Onalespib is under clinical development by Astex Pharmaceuticals and currently in Phase I for Solid Tumor. According to GlobalData, Phase I drugs for Solid Tumor have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Onalespib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Onalespib (AT-13387) is under development for the treatment of metastatic triple negative breast cancer, relapsed and refractory anaplastic large cell lymphoma (ALCL), mantle cell lymphoma, diffuse large B-cell lymphoma, advanced squamous cell carcinoma of the oral cavity, oropharynx, hypopharynx, or larynx, head and neck, recurrent ovarian, fallopian tube, primary peritoneal and HPV associated cancer. The drug candidate is administered intravenously. AT13387 is a second-generation, fully synthetic small molecule. It acts by inhibiting HSP90. It is developed based on Pyramid technology. It was also under development for the treatment of castration-resistant prostate cancer, HER-2 positive breast cancer, non-small cell lung cancer (NSCLC) and refractory gastrointestinal stromal tumors (GIST).
Astex Pharmaceuticals overview
Astex Pharmaceuticals, a subsidiary of Otsuka Holdings Co Ltd, is a drug discovery and development company with a focus on cancer and central nervous system (CNS) diseases. The company’s proprietary fragment-based drug discovery platform, Pyramid delivers high-quality and customized drug leads across a variety of therapeutic targets and disease areas. Its pipeline product and programs include DNMT inhibitor, Oral DNMT inhibitor, dual IAP antagonist, oral murine double minute 2 (MDM2) antagonist and extracellular signal-related protein kinases inhibitor. Astex Pharmaceuticals is also advancing several of its compounds into clinical trials in collaboration with Novartis, AstraZeneca, GSK, and Janssen. The company operates as a subsidiary of Otsuka Pharmaceutical Co Ltd. Astex Pharmaceuticals is headquartered in Pleasanton, California, the US.
For a complete picture of Onalespib’s drug-specific PTSR and LoA scores, buy the report here.